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Clinical trial data available thus far have been obtained primarily in patients with resistant hypertension, deﬁned as
standardized systolic clinic blood pressure 160 mm Hg (or 150 mm Hg in patients with type 2 diabetes) despite
appropriate pharmacologic treatment with at least 3 antihypertensive drugs, including a diuretic agent. Accordingly,
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2032Scope of the Expert
Consensus Statement
Resistant hypertension is a com-
mon and growing yet neglected
clinical problem. General practi-
tioners and specialist physicians
are frequently faced with the chal-
lenging task of managing these
patients. A novel interventional
treatment approach based on tran-
sluminal radiofrequency (RF) ab-
lation of renal nerves has recently
been introduced into clinical med-
icine in Australia, Europe, and
other countries and has sparked
substantial interest from affectedpatients, treating and referring practitioners and physicians,
interventionalists, and health care providers. In view of the
limited clinical trial data available, it appeared timely and
important to summarize the views of an international panel to
provide some guidance with regard to the indications, methods,
and safety of transluminal renal nerve ablation. The recom-
mendations in this statement are based on the interpretation of
clinical trial data available to date and are intended to facilitate
a better understanding of the safety, effectiveness, and limitations
of this technology, with a particular focus on appropriate patient
selection.
There is a lack of data on the exact prevalence of resistant
hypertension, which is commonly deﬁned as blood pressure
(BP) higher than target levels despite the use of 3 antihy-
pertensive agents in adequate doses from different classes,
including a diuretic agent (1). Evidence from the National
Health and Nutrition Examination Survey and from largeementwas the direct work product ofmembers of
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olish Science (KOLUMB/2010-1). Dr. Katholirandomized clinical trials indicates that 20% to 30% of
patients with hypertension require 3 or more antihyperten-
sive agents to achieve BP targets. Recent data from the
National Health and Nutrition Examination Survey indicate
that 12.8% of the antihypertensive drug–treated population
fulﬁlled the criteria of resistant hypertension (2). Data from
a large Spanish registry suggested that resistant hypertension
is present in 12% of the treated hypertensive population,
but among them, more than one-third have normal ambu-
latory BP (3). Data from 205,750 patients with incident
hypertension revealed that 1.9% developed resistant hyper-
tension within a median of 1.5 years from initial treatment
(0.7 cases per 100 person-years of follow-up) (4). Failure to
reach target BP levels despite therapeutic intervention leaves
patients at high risk for major cardiovascular events (4,5).
Sympathetic nervous system and BP control. The
sympathetic nervous system plays an important role in
circulatory and metabolic control and is a major contributor
to the development of hypertension (6,7), mediated via
sodium and water retention, increased renin release, and
alterations of renal blood ﬂow. Accordingly, direct targeting
of the sympathetic nervous system is a logical therapeutic
approach for the treatment of hypertension.
Speciﬁc role of renal nerves for hypertension and
cardiovascular outcomes. The kidneys have a dense af-
ferent sensory and efferent sympathetic innervation. Renal
sensory afferent nerve activity directly inﬂuences sympathetic
outﬂow to the kidneys and other highly innervated organs
involved in cardiovascular control (8,9) (Fig. 1). Afferent
and efferent sympathetic nerves can interact to modulate
sympathetic activity (10). Abrogation of renal sensory afferent
nerves reduces both BP and organ-speciﬁc damage caused
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Figure 1 Effects of Afferent Renal Nerve Signaling
Various triggers, such as renal injury and ischemia, can stimulate afferent signaling from the kidney to central integrative nuclei, with the consequence of exaggerated efferent
sympathetic outﬂow to target organs, including the heart, the vasculature, the kidneys, and other organs involved in both cardiovascular and metabolic control, as illustrated.
Renal denervation, by targeting both efferent and afferent nerves as can be achieved by catheter-based application of radiofrequency energy, may be useful to effectively
interrupt this vicious cycle. OSA ¼ obstructive sleep apnea; pCO2 ¼ partial pressure of carbon dioxide; RAAS ¼ renin-angiotensin-aldosterone system.
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2033models (11,12). Although afferent activity cannot be quan-
tiﬁed in humans, there is strong evidence that it modulates
the level of central sympathetic outﬂow. Assessment of re-
gional overﬂow of norepinephrine (NE) from the kidneys to
plasma has demonstrated that renal NE spillover rates can
be markedly elevated in patients with essential hypertension
(13) and are associated with hypertensive end-organ damage
such as left ventricular hypertrophy (14).Catheter-Based Renal Nerve Ablation
Method. Against this background, a novel catheter-based
approach to selectively denervate the human kidneys was
recently introduced (15). In this approach, renal nerve
ablation is achieved percutaneously via the lumen of the
renal artery using RF energy. Other treatment modalities,
such as ultrasound, cryoablation, and perivascular delivery of
neurotoxins, are currently being investigated and brieﬂy
reviewed in the Online Appendix. Although most intra-
luminal approaches share many of the principal features, the
approach for RF ablation used in the clinical trials currently
available is described here.
Access to the renal artery is typically gained using a 6-F to
9-F sheath introduced into the femoral artery. A renal artery
angiogram is obtained to assess anatomic suitability and to
exclude signiﬁcant renal artery stenosis or other relevant
renal artery pathology. Each renal artery should have a
diameter of 4 mm and a length of 20 mm to allow
adequate application of RF energy and a sufﬁcient number
of RF ablation treatments (4). Smaller dimensions may
interfere with the application of RF energy because of lowerblood ﬂow and reduced cooling effects and may predispose
to vascular spasm. Local application of vasodilators such as
nitroglycerin may be useful to prevent or revert spasm of
renal arteries.
To identify abnormal vascular anatomies that may inter-
fere with the ablation procedure, renal vascular imaging
should be carried out before renal denervation (RDN). An
aortogram obtained before selective renal angiography at the
time of intervention is helpful to identify the presence of
multiple renal arteries.
The treatment catheter is introduced through a 6-F
to 9-F guiding catheter into the renal artery and placed
distally before the ﬁrst branch of the renal artery under
ﬂuoroscopic guidance to ensure close and stable contact with
the vessel wall. Discrete low-energy RF ablations are then
applied from distally to proximally within each renal
artery (Fig. 2). RF ablation in areas with atherosclerotic
plaques should be avoided. The duration of the procedure is
typically 30 to 60 min. Minor vascular irregularities likely
representing intimal edema can often be observed directly
after the procedure at the treatment sites. These are typically
not ﬂow limiting and commonly resolve by the end of the
procedure.
Periprocedural and post-procedural management. PAIN
MANAGEMENT. The ablation procedure is typically accom-
panied by diffuse, visceral, nonradiating abdominal pain,
which does not persist beyond the RF energy application
and should be managed using intravenous analgesic and
anxiolytic or sedative medications. Vital signs, including
BP, heart rate, and oxygen saturation, should be monitored
during the procedure.
Figure 2
Schematic Illustration of the Percutaneous
Catheter-Based Approach to Functionally
Denervate the Human Kidney
Similar to routine angiography, access to the renal artery is obtained through
a sheath in the femoral artery. The treatment catheter is then introduced into the
renal artery through a guiding catheter, and discrete radiofrequency (RF) ablation
treatments lasting 2 min each are applied along the renal artery, as illustrated. At
least 4 ablations are performed in each artery, which are separated both longi-
tudinally (by at least 5 mm) and rotationally to achieve circumferential coverage of
the renal artery. Catheter tip temperature and impedance are constantly monitored
during ablation and RF energy delivery is regulated according to a pre-determined
algorithm.
Schlaich et al. JACC Vol. 62, No. 22, 2013
Expert Consensus Statement: Transluminal Radial Denervation for Resistant Hypertension December 3, 2013:2031–45
2034SYSTEMIC ANTICOAGULATION AND ANTIPLATELET THERAPY.
Before the procedure, appropriate systemic anticoagulation
should be attained and veriﬁed by activated clotting time, with
a target of 200 to 250 s. Recent data from a porcine model (16)
and from human studies using optical coherence tomography
(17) demonstrate the possible occurrence of endothelial-
intimal edema and thrombus formation. Periprocedural anti-
platelet therapy may therefore be advisable in patients
undergoing RDN. Although this has not been investigated in
clinical trials, the use of 250 mg of acetylsalicylic acid during
the procedure and 75 to 100 mg/day for up to 4 weeks after
RDN has been suggested (18).
ASSESSMENT OF EFFICACY. It is important to note that BP
rarely changes directly after the procedure. It often takes
several weeks to months for BP reductions to occur. Patients
should be informed accordingly to avoid unrealistic expec-
tations. Currently, there is no reliable clinical parameter
available that would allow the prediction of the BP response
in an individual patient or to assess the degree of RDN
achieved. The exact mechanisms by which RDN results in
a BP reduction are not yet fully established but seem to
include a reduction in sympathetic activation, total periph-
eral resistance, renin release, and alterations of water and
sodium handling.
There is currently no readily available variable to monitor
the efﬁcacy of the procedure itself. Conceptually, assessmentof muscle sympathetic nerve activity (MSNA) would be
a good candidate variable for this purpose, but the method is
not suitable for everyday clinical practice. Nevertheless, in
a report on a single patient, a progressive reduction in
MSNA was obtained over time and paralleled by a reduction
in BP (19). Data from a larger cohort of 25 patients with
resistant hypertension conﬁrm a signiﬁcant reduction in
MSNA after RDN (20).
Theoretically, a lack of effect on BP could be explained by
1 or more of these 3 factors: 1) a procedure failure, that is,
that the procedure did not result in sufﬁcient ablation of
nerves to provoke a BP-lowering response; 2) a pathophysi-
ology failure, that is, that overactivity of renal nerves was
not a signiﬁcant contributor to the elevated BP in a given
patient; and 3) despite the procedure being technically
successful, the cardiovascular system is unable to respond
with a lowering of BP, for instance because of arteries that
are too stiff or calciﬁed to dilate. Thus far, it is impossible to
clearly distinguish among these possibilities.
Clinical studies. Clinical data are currently available from 2
trials assessing the safety and efﬁcacy of RDN (15,21). Both
of these studies were carried out in patients who
were resistant to conventional pharmacologic treatment as
deﬁned by the failure to achieve systolic BP <160 mm Hg
(or <150 mm Hg in patients with diabetes) despite ad-
equate doses of at least 3 antihypertensive drugs from
different classes, typically including a diuretic agent (1).
THE SYMPLICITY HTN-1 TRIAL. The initial trial (Symplicity
HTN-1 [Renal Sympathetic Denervation in Patients With
Treatment-Resistance Hypertension]) was designed as
an observational ﬁrst-in-human evaluation of the safety
and BP-lowering efﬁcacy of selective RDN (15). A total of
45 consecutive patients (mean age 58  9 years) with a mean
BP of 177/101  20/15 mm Hg were included. Patients
were on a mean of 4.7  1.5 antihypertensive drugs. The
procedure was associated with signiﬁcant reduction in both
systolic and diastolic ofﬁce BPs at 1, 3, 6, 9, and 12 months,
with mean decreases in ofﬁce BP of 14/10  4/3, 21/
10  7/4, 22/11  10/5, 24/11  9/5, and 27/
17  16/11 mm Hg, respectively. To assess physiological
responses to RDN, radiotracer dilution methodologies were
applied to assess the overﬂow of NE from the kidneys into
the circulation before and after the procedure. Analyses from
10 patients revealed a substantial reduction in mean NE
spillover of 47% (95% conﬁdence interval: 28% to 65%) at
1 month after bilateral denervation.
THE SYMPLICITY HTN-2 TRIAL. After this ﬁrst-in-human proof-
of-concept and safety study, a randomized controlled clinical trial
(Symplicity HTN-2) was initiated that included a total of 106
patients from 24 centers in Australia and Europe (21). Patients
were randomized in a 1:1 ratio to renal ablation treatment (n ¼
52) or a control group (n¼ 54). Both groups had similar baseline
characteristics and antihypertensive regimen with the exception
of estimated glomerular ﬁltration rate (eGFR), which was lower
in the active treatment group (77 vs. 86 ml/min, p ¼ 0.013).
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2035The difference in the primary endpoint of seated ofﬁce
BP between the RDN group and the control group was 33/
11 mm Hg (p < 0.001 for both systolic and diastolic BP),
resulting in a mean BP of 147/84 mm Hg in the RDN group
at 6 months (from 178/96 mm Hg at baseline, p < 0.001),
while no change in BP was observed in the control
group (178/97 mm Hg at baseline and 179/96 mm Hg
at 6 months, p ¼ 0.77) (Fig. 3). Home BP recordings
conﬁrmed the observed ofﬁce BP changes, with reductions
by 20  17 mm Hg systolic and 12  11 mm Hg diastolic
in the RDN group. In contrast, systolic (2  13 mm Hg)
and diastolic (0  7 mm Hg) home BP did not change
signiﬁcantly in the control group. The absolute difference
between the groups was 22/12 mm Hg (p < 0.001).
Ambulatory BP measurements were available from only
20 patients in the treatment group and 25 patients in
the control group. Ambulatory systolic BP was reduced
by 11  15 mm Hg (p ¼ 0.006) and ambulatory diastolic
BP by 7  11 mm Hg (p ¼ 0.014) at 6 months post-
procedurally in the RDN group, whereas no changes were
observed in the control group (systolic BP:3 19 mmHg;
diastolic BP: 1  12 mm Hg). RDN resulted in control
of BP, deﬁned as systolic BP <140 mm Hg, in 39% of
patients, whereas only 3% of patients in the control group
achieved BP control. Twenty percent of the patients
who underwent RDN had reductions in drug treatment
before the 6-month follow-up visit, whereas antihy-
pertensive drug treatment was reduced in only 6% patientsFigure 3 Changes in Ofﬁce DBP and SBP in the RDN Group and the
*p < 0.0001, yp ¼ 0.002, zp ¼ 0.005. Reprinted with permission from Esler et al. (21)
denervation; SBP ¼ systolic blood pressure; Symplicity HTN ¼ Renal Sympathetic Denerin the control group (p ¼ 0.04). Eight percent of patients
in the RDN group and 12% of patients in the control
group had increases in drug treatment before the 6-month
follow-up visit (p ¼ 0.74).
Recently published data on longer-term follow-up, in-
cluding 6-month crossover results, indicate that 12 months
after the procedure, the mean decrease in ofﬁce systolic
BP in the initial RDN group was similar to the 6-month
decrease. The mean systolic BP of the crossover group
6 months after the procedure was also signiﬁcantly lowered
(from 190.0  19.6 to 166.3  24.7 mm Hg, a change
of 23.7  27.5 mm Hg; p < 0.001) (22).
THE SYMPLICITY HTN-3 TRIAL. Following the unblinded
evidence from Symplicity HTN-1 and Symplicity HTN-2,
to eliminate the possibility that patient awareness of
the procedure or subconscious observer bias might be
contributing, a larger multicenter, prospective, single-blind,
randomized controlled study of the safety and effectiveness
of RDN in subjects with uncontrolled hypertension is
currently ongoing in the United States, the Symplicity
HTN-3 trial. The inclusion criteria are very similar to those
of Symplicity HTN-2, with even more stringent medication
requirements, as described in detail elsewhere (23). A
total of 530 patients with resistant hypertension will
be randomized in a 2:1 ratio to undergo either RDN or
a sham procedure. Additionally, all subjects will undergo
ambulatory blood pressure monitoring (ABPM). ResultsControl Group in the Symplicity HTN-2 Trial
. ANOVA ¼ analysis of variance; DBP ¼ diastolic blood pressure; RDN ¼ renal
vation in Patients With Treatment-Resistant Hypertension.
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2036are expected to be available in early 2014 and will provide
valuable information with reduced scope for behavioral
bias.
REAL-WORLD EXPERIENCE. An increasing number of reports
on smaller case series are available. A recent report published
in abstract form summarizes the experience from 8 Euro-
pean centers (24). Ofﬁce and ambulatory BP measurements
were extracted from the medical ﬁles of 73 patients with
resistant hypertension before and 6 months after RDN.
Ofﬁce systolic and diastolic BP decreased by 18.7  2.7/7.5
 1.7 mm Hg (p < 0.001), while ambulatory systolic and
diastolic BP decreased by 6.7  2.1/4.2  1.3 mm Hg
(p ¼ 0.002). The proportion of patients with reductions in
systolic ofﬁce BP of >10 mm Hg was 64%.
The relevance of drug adherence has been highlighted
by a small observational study (25). To be eligible for
RDN, patients required an ambulatory daytime systolic BP
>135 mm Hg after witnessed intake of their antihyperten-
sive drugs. When these criteria were applied, only 6 of
18 patients were still eligible for RDN. This study docu-
ments the insidious nature of pharmaceutical nonadherence
and reinforces the need for chronic hypertension therapies
that respect patient choice not to adhere to long-term
polypharmacy.
Another recent report summarizes data from 346
uncontrolled hypertensive patients from 10 centers in
Europe and Australia (26). Patients were separated accord-
ing to daytime ABPM into 303 with true-resistant hyper-
tension (ofﬁce systolic BP 172.2  22 mm Hg, 24-h systolicFigure 4
Changes in Ofﬁce DBP and SBP and ABP in Patients With
Those With Pseudoresistant Hypertension
Reprinted with permission from Mahfoud et al. (26). ABP ¼ ambulatory blood pressure; DBP 154  16.2 mm Hg) and 43 with pseudoresistant
hypertension (ofﬁce systolic BP 161.2  20.3 mm Hg, 24-h
systolic BP 121.1  19.6 mm Hg). At 3-month, 6-month,
and 12-month follow-up, ofﬁce SBP was reduced by 21.5,
23.7, and 27.3 mm Hg and ofﬁce diastolic BP by 8.9, 9.5,
and 11.7 mm Hg (n ¼ 245, 236, and 90, p < 0.001 for all),
respectively. In patients with true treatment resistance,
signiﬁcant reductions in 24-h systolic BP (10.1, 10.2,
and11.7 mmHg, p< 0.001) and diastolic BP (4.8,4.9,
and 7.4 mm Hg, p < 0.001) were evident at 3, 6, and
12 months, respectively. Although ofﬁce BP was reduced to
a similar extent in patients with pseudoresistant hyper-
tension, no effect onBP as assessed byABPMwas observed in
this cohort (Fig. 4).
More recently, the effects of RDN on BP in patients with
moderately resistant hypertension (i.e., ofﬁce BP 140/
90 mm Hg despite the use of at least 3 antihypertensive
drugs, including a diuretic agent, in adequate doses) were
described (27). In this study, a total of 54 patients with ofﬁce
BP 140/90 and <160/100 mm Hg and conﬁrmed diag-
noses of resistant hypertension by 24-h ABPM (BP 130/
80 mm Hg) underwent RDN. At 6 months after
the procedure, ofﬁce BP was reduced by 13/7 mm Hg
(systolic: 151  6 vs. 138  21 mm Hg, p < 0.001; dia-
stolic: 83  10 vs. 75  11 mmHg, p < 0.001). Ambulatory
BP measurements were available from 36 patients and
revealed a reduction in mean 24-h BP of 14/7 mm Hg.
In 51% of patients, ofﬁce BP was controlled to <140/90
mm Hg after RDN.True Treatment-Resistant Hypertension and
BP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure.
Figure 5
Mean Systolic and Diastolic BP Changes From
Baseline After Renal Denervation With Up to
2 Years of Follow-Up in the Symplicity HTN-1 Trial
Reprinted with permission from Symplicity HTN-1 Investigators (31). BP ¼ blood
pressure.
JACC Vol. 62, No. 22, 2013 Schlaich et al.
December 3, 2013:2031–45 Expert Consensus Statement: Transluminal Radial Denervation for Resistant Hypertension
2037Another smaller study in a similar cohort of 20 patients
with ofﬁce systolic BPs of 140 to 160 mm Hg despite 3
antihypertensive medications who underwent RDN revealed
BP reductions of a similar magnitude of 13.1 13.6 mmHg
systolic and 5.0  8.3 mm Hg diastolic ofﬁce BP at
6 months (28). Compared with baseline, the mean ambula-
tory systolic and diastolic 24-h BPs were reduced by 11.3 
8.6 and 4.1 7.3mmHg at 6months, respectively. Although
these preliminary data are encouraging, other studies suggest
that patients with milder resistant hypertension do not
show consistent decreases in BP at 3 or 6 months after
RDN (29).
In this context, it is noteworthy that the reduction in mean
BP on ABPM after RDN was generally less pronounced than
the reduction in ofﬁce BP. This is not surprising and a well-
known phenomenon observed in many other BP-lowering
trials. However, the magnitude of the difference between
ofﬁce and ambulatory BP changes appears to be somewhat
more pronounced than that observed in BP-lowering trials
using pharmacological approaches, as recently discussed in
detail (30) (Online Fig. 1).
LONGER-TERM EFFICACY. The long-term durability of the
procedure remains an important question. A recent analysis
of patients treated with catheter-based RDN in a non-
randomized and uncontrolled fashion (total n ¼ 153)
demonstrated reductions in mean ofﬁce BP of 23/11, 26/
14, and 32/14 mm Hg at 12-month, 18-month, and
24-month follow-up (31), respectively (Fig. 5). Very re-
cently, data on an expanded group of patients from that
cohort including 59 patients who had been followed through
to 2 years and 24 patients through to 3 years after RDN
have been presented and demonstrated that the mean BP
change after RDN was 33/15 mm Hg at 2 years and 33/
19 mm Hg at 3 years, with increasing rates of BP response
deﬁned as a reduction of systolic BP of >10 mm Hg over
time. These data indicate that RDN results in signiﬁcant
and durable reductions of systolic BP in patients with
treatment-resistant hypertension and suggest that even
patients with minimal initial reductions in BP may have
signiﬁcant reductions later on, a ﬁnding that needs to be
taken into account should a repeated RDN procedure ever
be considered. Further and longer studies are required to
ascertain the durability of RDN.
SAFETY. In Symplicity HTN-1, vascular safety analysis con-
sisting of renal angiography at 14 to 30 days after the pro-
cedure and magnetic resonance angiography at 6 months after
the procedure revealed no instances of renal artery aneurysm
or stenosis or other long-term adverse events. Using the ﬁrst-
generation RF catheter, 1 renal artery dissection occurred in
1 patient before energy delivery, which required stenting
and resolved without further adverse consequences. Renal
function was not compromised. The impact on eGFR was
neutral with 1.4 ml/min (95% conﬁdence interval: 4.6 to
1.7 ml/min) at 3 months and 2.8 ml/min (95% conﬁdence
interval: 6.4 to 0.8 ml/min) at 12 months. In the extendedSymplicity HTN-1 cohort (n ¼ 153), a total of 3 groin
pseudoaneurysms occurred. One patient required stenting of
a renal artery ostial stenosis that was present at baseline but
had grown by 6 months. Of note, no RF energy had been
delivered in this location.
In Symplicity HTN-2, periprocedural events requiring
treatment were rare and consisted of 1 femoral artery
pseudoaneurysm, 1 post-procedural decrease in BP resulting
in a reduction in antihypertensive drugs, 1 urinary tract
infection, 1 extended hospital admission for assessment of
paraesthesia, and 1 case of back pain that was treated with
analgesics and resolved after 1 month. Seven of 52 patients
(13%) who underwent RDN had transient intraprocedural
bradycardia requiring atropine. Renal function, as assessed
by serum creatinine, eGFR, and cystatin C levels, were
unchanged from baseline in both groups at 6 months. Six-
month renal vascular imaging identiﬁed 1 patient with
possible progression of an underlying atherosclerotic lesion,
which required no therapy.
Two recently published case reports describe the devel-
opment and progression of a renal artery stenosis (32,33)
and a potential link with the RDN procedure. Long-term
follow-up of treated patients with repeat imaging of the
renal arteries will be required to adequately address this
issue.
In addition toBP lowering, RDNhas been shown to reduce
heart rate (34) (Fig. 6) and to reduce BP during exercise
without compromising chronotropic competence (35).Additional Potential Beneﬁcial Effects of
Renal Denervation
A series of studies have reported on the effects of RDN on
aspects other than BP reduction. The majority of these
studies were observational and uncontrolled and comprised
Figure 6
Changes in HR According to HR Tertiles at Baseline in
136 Patients With Resistant Hypertension Who
Underwent Renal Denervation
Values are mean  SEM. The p values are for comparisons with baseline.
Reprinted with permission from Ukena et al. (34). ANOVA ¼ analysis of variance;
HR ¼ heart rate.
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therefore need to be interpreted with appropriate caution.
Clearly, larger, adequately designed studies are necessary,
and many are currently being undertaken to conﬁrm or reject
these initial ﬁndings. Nevertheless, pathophysiologic
considerations suggest that some of these initial ﬁndings
may have potential clinical relevance.
Glucose metabolism. Hypertension is frequently associ-
ated with metabolic alterations. Sympathetic activation has
been identiﬁed as an important contributor to this detri-
mental clinical scenario (36). Sympathoinhibition would
therefore be expected to improve glycemic control (37). In
a subcohort of the Symplicity HTN-2 trial, patients from
both the RDN (n ¼ 37) and control groups (n ¼ 13)
underwent detailed assessment of glucose metabolism.
Levels of fasting glucose, insulin, C-peptide, glycosylated
hemoglobin, and calculated insulin sensitivity (homeostasis
model assessment of insulin resistance) improved signiﬁ-
cantly after 3 months. Mean 2-h glucose levels during oral
glucose tolerance tests were also reduced signiﬁcantly by
27 mg/dl (p ¼ 0.012), while there were no signiﬁcant
changes in BP or in any of the metabolic markers in the
control group (38) (Fig. 7).
Left ventricular hypertrophy. Additional factors that may
translate into better outcomes after RDN include improve-
ments in cardiac baroreﬂex sensitivity and a reduction in left
ventricular mass (19). These initial ﬁndings from a single
case report have now been conﬁrmed in a larger cohort of 46
patients with resistant hypertension for which they under-
went RDN (39). RDN was not only associated with
substantial reductions in systolic and diastolic BP (22.5/7.2 mm Hg at 1 month and 27.8/8.8 mm Hg at 6
months, p < 0.001 at each time point) but also signiﬁcantly
reduced mean interventricular septal thickness and LV mass
index at 1 and 6 months, respectively (Fig. 8). Diastolic
function was also improved, as assessed by mitral valve
lateral E/E ratio, which decreased after RDN from 9.9  4.0
to 7.9  2.2 at 1 month and 7.4  2.7 at 6 months (p <
0.001), indicating reduction of left ventricular ﬁlling pres-
sures. No such changes were observed in a matched group of
18 control patients. These data may indicate that the effects
of RDN go beyond that of merely reducing BP and may
contribute to regression of hypertensive end-organ damage.
Atrial ﬁbrillation. Both animal and human studies suggest
that the autonomic nervous system plays an important role
in the initiation and maintenance of atrial ﬁbrillation (AF).
A recent study by Pokushalov et al. (40) reported that RDN
reduced AF recurrence when combined with pulmonary vein
isolation (PVI). In this study, 27 patients with hypertension
with histories of symptomatic paroxysmal or persistent AF
were enrolled, 14 of whom underwent PVI only and 13 of
whom were treated with PVI and RDN. At 12-month
follow-up, patients in the PVI plus RDN group experi-
enced signiﬁcant reductions in systolic (from 181  7 to 156
 5 mm Hg, p < 0.001) and diastolic (from 97  6 to 87 
4 mm Hg, p < 0.001) BP and had a substantially lower rate
of recurrence of AF. Nine of the 13 patients (69%) treated
with PVI plus RDN were free of AF, whereas this was the
case in only 4 of the 14 patients (29%) in the PVI-only
group (p ¼ 0.033). Although optimized BP control might
play a considerable role in decreasing the development of
recurrence of AF, this study raises the possibility that
reducing sympathetic drive with RDN may reduce the rate
of AF recurrence in patients with resistant hypertension.
However, in a recent letter to the editor, several concerns
were raised pertaining to the design of the study, insufﬁcient
description of methods, and inconsistencies with data
reporting and statistics (41). Further studies are needed to
assess the therapeutic potential of RDN in the setting of AF.
Heart failure. Heart failure is commonly characterized by
substantial neurohormonal activation directed particularly to
the heart and kidneys, providing a theoretical basis for the
potential usefulness of targeting renal nerves with RDN in
this context. A small pilot study including 7 patients with
chronic mild to moderate systolic heart failure (mean ejec-
tion fraction 43  15%) did not raise any procedural or
safety concerns (42), particularly no major decrease in BP
despite low baseline levels and no change in renal function,
and demonstrated a mild improvement in 6-min walking
distance, while ejection fraction and other cardiac structural
and functional changes were not changed signiﬁcantly after
6 months. Larger clinical trials are ongoing to delineate the
potential role of RDN in heart failure.
Chronic and end-stage kidney disease. Sympathetic
activation is a hallmark of chronic kidney disease but
generally neglected as a therapeutic target (43). Given the
relevance of both renal efferent and afferent nerves in this
Figure 7 Changes in Fasting Glucose, Fasting Insulin, C-Peptide, and HOMA-IR
Change (SEM) in fasting glucose (A), fasting insulin (B), C-peptide (C), and homeostasis model assessment-insulin resistance (D) at 1 and 3 months after renal denervation
compared with baseline. Reproduced with permission from Mahfoud et al. (38). ANOVA ¼ analysis of variance; HOMA-IR ¼ homeostasis model of assessment of insulin
resistance.
JACC Vol. 62, No. 22, 2013 Schlaich et al.
December 3, 2013:2031–45 Expert Consensus Statement: Transluminal Radial Denervation for Resistant Hypertension
2039condition (11,12), these patients may derive speciﬁc beneﬁt
from an intervention targeting the renal nerves (44). A
recent proof-of-concept study in 15 patients with resistant
hypertension (mean BP 174  22/91  16 mm Hg despite
the use of 5.6  1.3 antihypertensive drugs) and moderate to
severe chronic kidney disease (mean eGFR 31.2  8.9 ml/
min/1.73 m2) in whom ofﬁce and ambulatory BP and
serum biochemistry were obtained before and at 1-month,
3-month, 6-month, and 12-month follow-up after RDN
revealed a favorable safety proﬁle with no compromise of
treated arteries evident on angiographic evaluation and
preserved renal function up to 12-months follow-up (45).
Ofﬁce systolic and diastolic BP decreased by 32  18/
15  12 mm Hg at 6-month follow-up (p < 0.001).
Nighttime ambulatory BP was signiﬁcantly reduced
(p < 0.05), resulting in restoration of a more physiologic
dipping pattern (45). Although renal hemodynamic status
has not been assessed in this chronic kidney disease cohort,
recent data from a larger cohort of 100 patients with resistant
hypertension and eGFRs >45 ml/min/1.73 m2 demon-
strated that RDN reduced the renal resistive index
at 3-month and 6-month follow-up (46). Although mean
cystatin C, eGFR, and urinary albumin excretion remained
unchanged after RDN, the number of patients with micro-
albuminuria or macroalbuminuria decreased (46). Whether
these potentially beneﬁcial changes in renal hemodynamic
status may translate into improved renal outcomes in patients
with resistant hypertension and various stages of chronic
kidney disease needs to be determined.Sympathetic tone is substantially enhanced in patients with
end-stage renal disease and may play a role in the high rate of
cardiovascular events in these patients (47). Nephrectomy of
the native nonfunctioning kidney in patients with or without
kidney transplantation resulted in a reduction ofMSNA (48).
A preliminary proof-of-concept study of RDN was per-
formed in 12 patients with end-stage renal disease and
uncontrolled hypertension (49). Standardized BP measure-
ments were obtained in all patients on dialysis-free days
at baseline and follow-up. The mean ofﬁce BP was 170.8/
89.2 mm Hg despite the use of a mean of 3.8  1.4 antihy-
pertensive drugs. Three of 12 patients could not undergo
RDN because of atrophic renal arteries. Compared with
baseline, ofﬁce systolic BP was reduced (from 166  16.0 to
148  11, 150  14, and 138  17 mm Hg, respectively),
whereas there was no change in the 3 nontreated patients.
Measures of renal NE spillover and MSNA were available
in 2 patients before and after RDN, and these markers were
substantially reduced by RDN. These initial results in-
dicate that there is high sympathetic drive in end-stage renal
disease, and it can be reduced by RDN, resulting in a signif-
icant BP reduction. Whether this translates into improved
outcomes in these high-risk patients requires conﬁrmation
in appropriately designed, larger population studies.
Patient Selection
On the basis of the available data from clinical studies,
only those patients who have severe treatment-resistant
Figure 8
Changes in LVH After Bilateral RD in 46 Patients With Resistant Hypertension Compared With 18 Control Patients
Who Did Not Undergo Renal Denervation
Comparison of LVMI (A), IVSTd (B) and reduction of LVMI (C) between the RDN and control group, and individual changes in LVMI in patients who did undergo RD (D) at various
time points. Reprinted with permission from Brandt et al. (39). LVH ¼ left ventricular hypertrophy; LVMI ¼ left ventricular mass index; IVSTd ¼ end-diastolic interventricular
septum thickness; RD ¼ renal denervation.
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(150 mm Hg in patients with type 2 diabetes) despite
treatment with 3 antihypertensive drugs of different types,
including one diuretic agent, at adequate doses should
undergo renal nerve ablation (Fig. 9). Elevated BP should be
conﬁrmed by 24-h ABPM, because up to one-third of
patients with treatment-resistant hypertension have normal
BP outside the ofﬁce (50). Every effort should have been
made to identify and reverse contributing lifestyle factors
and discontinue or minimize the use of substances that can
increase BP. Secondary causes of hypertension should have
been re-evaluated and excluded, as previously summarized
(51) (Table 1). Careful attention should have been paid to
exclude nonadherence to drug therapy as an important and
often neglected cause of treatment resistance (52). The
importance of systematic screening to assess eligibility for
RDN was highlighted in a recent study demonstrating that
2 of 3 patients with suspected resistant hypertension were
found to be ineligible if the aforementioned criteria were
applied, primarily because of previously undiagnosed
secondary hypertension, white coat hypertension, or BP
lower than currently recommended thresholds (53).
In the Symplicity HTN-1 and Symplicity HTN-2
studies, patients were excluded if renal function was
reduced to an eGFR <45 ml/min/1.73 m2. Contrast media
are administered during the procedure. Patients with
markedly reduced glomerular ﬁltration rates may beparticularly vulnerable to acquiring acute renal failure. The
cholesterol embolus syndrome is a potential risk if there is
renal atherosclerosis (54). Even in dialysis patients, loss of
residual renal function and diuresis may have a negative
impact on quality of life and prognosis. Currently, RDN in
patients with advanced chronic kidney disease (glomerular
ﬁltration rate <45 ml/min/1.73 m2) is therefore recom-
mended only in clinical trials.
Background therapy. Whether only patients who have
tried aldosterone antagonists should be eligible for renal
nerve ablation is controversial. Systolic BP reductions up to
25 mm Hg have been reported after administering spi-
ronolactone as a fourth antihypertensive agent (55,56), but not
all patients respond to such an extent. A randomized
controlled trial suggested that the incremental effect on ofﬁce
systolic BP was only 6.5 mm Hg (57). Long-term treatment
with spironolactone is hampered by side effects such as
gynecomastia, while eplerenone currently has the drawback of
relatively high cost. Furthermore, there is a risk for hyper-
kalemia with aldosterone antagonists, which requires moni-
toring. Although the incidence of hyperkalemia may
numerically be low, patients with treatment-resistant hyper-
tension in general receive already 1 or 2 agents blocking the
renin-angiotensin system and may already have reduced renal
function (eGFR <60 ml/min/1.73 m2), both factors that
increase the incidence of hyperkalemia. Spironolactone
increases potassium levels, especially in white subjects (58,59),
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Randomized Aldactone Evaluation Study was accompanied
by an increase in hospitalizations for hyperkalemia (60),
although this has been put in perspective by others (59).
Moreover, if unexpected circumstances occur that compro-
mise renal function, such as the administration of nonsteroidal
anti-inﬂammatory drugs or volume loss with diarrhea, the rate
of hyperkalemia may increase further. Thus, an individualized
approach balancing the pros and cons of lifelong administration
of aldosterone antagonists is preferential.
There is no sufﬁcient clinical research experience of renal
nerve ablation in the setting of hemodynamically or anatomi-
cally signiﬁcant renal artery abnormalities (e.g., stenosis or
ﬁbromuscular dysplasia), previous renal artery interventions
including previous renal stent procedures, unstable clinical
conditions (e.g., acute cardiovascular events), or in children or
patients with preeclampsia. These should, therefore, currently
be considered contraindications in routine clinical practice.
General requirements for sites involved in RDN
procedures. In patients with difﬁcult-to-control BP,
secondary forms of hypertension should be suspected and
excluded. RDN is not the ﬁrst-line therapy for such patients.
A detailed screening program should be completed to
exclude curable forms of secondary hypertension. Specialized
centers are typically best equipped to perform thorough
diagnostic investigations and provide the expertise and in-
frastructure for appropriate patient management and selec-
tion, procedure implementation, management of potential
complications, and the essential follow-up.
Although the clinical experience with RDN is mounting,
with more than 6,000 treated patients worldwide, it cannotFigure 9 Patient Assessment to Determine Eligibility for RDN
The ﬂowchart describes the recommended pathway to assess eligibility for renal denervat
a series of diagnostic tests to conﬁrm true treatment resistance. Furthermore, reversing of
RDN is considered. Throughout this process, communication between hypertension spec
patient’s care is essential. ABPM ¼ ambulatory blood pressure monitoring; BP ¼ blood p
ﬁltration rate; MRA ¼ magnetic resonance angiography; OSA ¼ obstructive sleep apnea;yet be rated as a standard procedure in resistant hyperten-
sion. It should be offered only to selected patients in
whom the present danger from hypertensive complications
such as death, myocardial infarction, and stroke exceed
the potential for long-term harm from the procedure,
for which the 36 months of follow-up of patients in
clinical trials may not yet be sufﬁcient to be deﬁnitively
excluded.
Patient follow-up. Regular follow-up visits after RDN are
necessary to assess short-term and long-term safety and
efﬁcacy and to adjust patients’ BP medications if required.
Given the known limitations of conventional clinic BP
readings, additional measures such as systematic home
BP monitoring (61) and ABPM should be implemented
as part of the follow-up of treated patients. The ﬁrst
scheduled follow-up should occur within the ﬁrst 4 weeks
after the procedure and then at 3, 6, and 12 months, with
subsequent yearly visits. In addition to BP measurements,
assessment of renal function (serum creatinine, eGFR,
electrolytes) is mandatory. Repeat renal artery imaging at
6 months or later after RDN is recommended to exclude
any post-procedural structural alterations, particularly if BP
has not dropped or has even increased. Depending on pre-
existing comorbidities, repeat electrocardiography, echo-
cardiography, assessment of glucose metabolism (fasting
glucose, insulin, glycosylated hemoglobin, oral glucose
tolerance test), measurement of urinary albumin and creat-
inine ratios and protein excretion, assessment of markers of
arterial stiffness, and other tests can provide additional
information on the therapeutic effects of RDN but are not
mandatory.ion (RDN). Patients who present with presumed treatment resistance should undergo
contributing factors and optimization of pharmacotherapy should be attempted before
ialists, interventional cardiologists, and other health care providers involved in the
ressure; CTA ¼ computed tomographic angiography; eGFR ¼ estimated glomerular
SBP ¼ systolic blood pressure; US ¼ ultrasound.
Table 1 Clinical Features and Diagnostics of Secondary Causes of Hypertension
Secondary Cause Clinical Features Screening Test
Additional/
Conﬁrmatory Test
Renal vascular
disease
 ARAS
 Rapid deterioration of renal
function (especially after
administration of
RAS-modulating agents)
 Onset of hypertension
after age 50 yrs
 Flash pulmonary edema
 Length difference 1.5 cm
between the kidneys
 FMD
 Early-onset hypertension
(particularly in young women)
 Renal duplex
ultrasonography
 MRI
 CT
 DSA
Renal parenchymal
disease
 Clinical history (including)
 Recurring UTI
 Analgesic abuse
 Familial diseases
 Anemia
 Fluid overload
 eGFR
 Urine dipstick
(e.g., erythrocytes,
leukocytes,
proteinuria)
 Urine albumin/
creatinine ratio
 Renal ultrasonography
 Kidney biopsy
(in reasonable cases)
Primary
hyperaldosteronism
 Muscle weakness
 Hypokalemia (occasional)
 Incidentaloma
 Aldosterone-renin
ratio (at best under
standardized
conditions)
 Oral sodium loading
 Saline infusion
 Fludrocortisone
suppression test
 Captopril challenge
 CT
 Adrenal vein sampling
OSA  Daytime hypersomnia
 Frequent nocturnal arousals
 Morning asthenia with or
without headache
 Severe snoring
 Speciﬁc
questionnaires
 Polygraphy
(ambulant)
 Polysomnography
(sleep center)
Drug-induced
hypertension
 Detailed medical history
(including OTC medicines)
Pheochromocytoma  Hypertension
(paroxysmal or sustained)
 Headache
 Sweating
 Palpitations
 Fasting hyperglycemia
 Incidentaloma
 Genetic predisposition
 Urinary fractionated
metanephrines
 Plasma-free
metanephrines
 CT
 MRI
 123I-labeled MIBG
scintigraphy
 Genetic screening
Cushing’s
syndrome
 Classical physical ﬁndings
 Central obesity
 Moon face
 Buffalo hump
 Red striae
 Hirsutism
 Glucose intolerance/diabetes
 Menstrual irregularities
 24-h urinary
cortisol excretion
 Dexamethasone
suppression test
 Exclusion of
exogenous
glucocorticoid
intake
 MRI
 CT
 CRH testing
Coarctation
of the aorta
 Headache
 Hypertension in the upper
extremities with lower extremity
pressure
 Discrepancies between bilateral
brachial blood pressure
 Congenital heart disease
 Chest radiography
 Echocardiography
 MRI
Reprinted with permission from Ott et al. (51).
ARAS ¼ atherosclerotic renal artery stenosis; CRH ¼ corticotropin-releasing hormone; CT ¼ computed tomography; DSA ¼ digital subtraction
angiography; eGFR ¼ estimated glomerular ﬁltration rate; FMD ¼ ﬁbromuscular dysplasia; MIBG ¼ metaiodobenzylguanidine; MRI ¼ magnetic
resonance imaging; OSA ¼ obstructive sleep apnea; OTC ¼ over-the-counter; RAS ¼ renin-angiotensin system.
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2043Study Limitations
The studies carried out so far have been restricted to patients
with severe and treatment-resistant hypertension with
systolic BP >160 mm Hg. These results cannot be simply
extrapolated to less severe forms or secondary forms of
hypertension.
Although uncontrolled, follow-up data are available beyond
3 years by now, this may not yet be sufﬁcient to ascertain the
long-term durability of the effect. Indeed, renal and heart
transplantation models indicate that renal nerves have the
potential to regrow anatomically after injury, raising the
possibility of ﬁnite time limits in the physiologic effects of the
procedure. However, on the basis of previous data, it appears
unlikely that the human kidney achieves functional reinner-
vation (62), and the physiologic importance of anatomic
regrowth of efferent nerve ﬁbers in sustaining BP remains
unproved. If functional reinnervation occurred, perhaps
mirrored by BP elevations, the issue of repeat renal nerve
ablation would have to be explored.
Theoretical concerns relate to the altered responsiveness
to certain stimuli in the absence of sufﬁcient renal sympa-
thetic innervation. The renal nerves are only 1 component
of the complex mechanisms that make up baroreceptor
function. For instance, the direct effects of the baroreceptor
arch on peripheral vascular resistance are unaffected. The
experience from kidney transplantation in humans, in
the process of which sympathetic nerves of the kidneys
are severed, is perhaps the most persuasive evidence to
demonstrate that the denervated kidney is capable of
maintaining electrolyte and volume homeostasis, suggesting
that selective ablation of renal nerves is unlikely to result in
adverse consequences.
Follow-up imaging of renal arteries 6 months after RDN
did not reveal evidence of major vascular damage. Published
data reporting on 2-year follow-up in a cohort of 153 patients
treated with RDN did not report major vascular abnormali-
ties. However, imaging studies of the renal vasculature were
not part of the routine investigation at 1-year and 2-year
follow-up.
Currently, there are no clinical trial data available to
indicate the effects of RDN on cardiovascular outcomes.
Several technical aspects also require attention. These
include the management of patients with dual renal arteries
and accessory arteries that may not be accessible for renal
nerve ablation, as well as the role of RDN in patients with
renal artery stenosis, a condition that is characterized not
only by activation of the renin-angiotensin system but also
by heightened sympathetic drive (63).
As indicated earlier, only a limited number of ambulatory
BP measurements were extractable from study-controlled
patients. In the Symplicity HTN-2 trial, only 20 patients
in the RDN group and 25 patients in the control group had
evaluable measurements (>70% successful readings) (21).
The difference in reduction of systolic BP after 6 months
was less pronounced, with only 8 mm Hg between the RDNand control groups. Whether this is a manifestation of
inadvertently biased measurement of BP by physicians aware
of treatment allocation or a reﬂection of a larger effect on the
alerting response is currently unknown. Ambulatory BP data
from the Symplicity HTN-3 trial will provide important
insights.
Finally, there is only limited information to what extent
the RDN procedure is able to interfere with afferent
sensory nerve trafﬁc and efferent sympathetic renal innerva-
tion. Elaborate microneurographic measurements (MSNA)
are currently the only way to quantify sympathetic nerve
activity. Further studies need to be conducted to address this
issue.
Conclusions
Evidence from the available clinical trials indicate that
catheter-based RF ablation of renal nerves improve BP
control in patients with resistant hypertension, with a safety
proﬁle to 3 years that seems acceptable for the degree and
reliability of BP improvement. The effects of RDN appear
to be mediated via interference with both efferent sympa-
thetic and afferent sensory nerves and may extend beyond
BP control.
RDN should currently be considered only in patients
whose BP cannot be controlled by a combination of lifestyle
modiﬁcation and pharmacologic therapy that is tailored
according to current guidelines.
It is not known whether RDN may be useful in less severe
forms of hypertension or in other conditions characterized
by heightened renal sympathetic nerve activity, such as heart
failure, metabolic syndrome, heart arrhythmias such as
AF, chronic and end-stage renal disease, and others. It is
therefore not recommended to perform RDN in these
patient cohorts outside of appropriately designed clinical
trials.
Information on the long-term safety and efﬁcacy of the
RDN procedure is being collected in national and interna-
tional registries.
Many uncertainties remain. One is the longer term, when
the risk for cardiovascular events grows, as does the oppor-
tunity to beneﬁt from event prevention; and meanwhile, the
potential for currently unrecognized complications might
grow along with the natural accumulation of unrelated
adverse events. A second is the suitability for patients outside
the idealized group of patients who tend to volunteer for
randomized controlled trials. A third is how to balance the
desirability of BP control, individual patients’ desire to feel
conﬁdent that their BP is controlled, their reluctance to take
very large numbers of tablets, their reluctance to undergo
irreversible and invasive procedures, and the cost of the
procedure versus the cost and consequences of letting BP
continue uncontrolled. While addressing these issues, an
accurate assessment of daily life BP control is an essential
requirement, and systematic use of home BP monitoring
and/or ABPM is thus mandatory. Clinicians must consider
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